GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (FRA:22Z) » Definitions » Other Gross PPE

Zealand Pharma AS (FRA:22Z) Other Gross PPE : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma AS Other Gross PPE?

Zealand Pharma AS's Other Gross PPE for the quarter that ended in Dec. 2024 was €0.00 Mil.

Zealand Pharma AS's quarterly Other Gross PPE declined from Jun. 2024 (€19.61 Mil) to Sep. 2024 (€17.29 Mil) and declined from Sep. 2024 (€17.29 Mil) to Dec. 2024 (€0.00 Mil).

Zealand Pharma AS's annual Other Gross PPE increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil) but then declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).


Zealand Pharma AS Other Gross PPE Historical Data

The historical data trend for Zealand Pharma AS's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Other Gross PPE Chart

Zealand Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 29.78 - - -

Zealand Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 19.81 19.61 17.29 -

Zealand Pharma AS Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Zealand Pharma AS Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines